AJCC	American Joint Committee on Cancer
CfmiR	Cell-free miR
CfDNA	Cell-free DNA
CfNA	Cell-free Nucleic Acids
CII	Checkpoint Inhibitor Immunotherapy
CR	Complete Response
CTLA-4	Cytotoxic T Lymphocyte-Associated Antigen 4
IRAE	Immune-Related Adverse Events
DE	Differentially Expressed
FC	Fold-Change
FDR	False Discovery Rate
GEO	Gene Expression Omnibus
MBM	Melanoma Brain Metastasis
miR	MicroRNA
NED	No Evidence of Disease
NGS	Next-Generation Sequencing
PD-1	Programmed Cell Death Protein-1
PD-L1	Programmed Cell Death Protein-1 Ligand
PD	Progressive Disease
PFS	Progressive-Free Survival
PR	Partial Response
NS	Non-Significant
RECIST	Response Evaluation Criteria In Solid Tumors 1.1
REMARK	Reporting Recommendations For Tumour Marker
SD	Stable Disease
LDH	Lactate Dehydrogenase
ULN	Upper Limit Normal
WTA	Whole Transcriptome Assay